Healthcare / Medical DevicesNasdaqGS
$3.60
+0.13 (+3.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-46.0M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$234M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-67.6%
↓Gross Margin
79.8%
↑Debt/Equity
0.82
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+32.4%
FCF CAGR
—
FCF margin
-13.9%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $212.7M · net income $-59.0M · FCF $-29.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $212.7M | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M | $57.4M | $39.4M |
| Net Income | $-59.0M | $-59.0M | $-55.7M | $-49.5M | $-42.8M | $-20.6M | $-3.7M | $-4.3M |
| EBITDA | $-43.1M | $-43.1M | $-42.1M | $-39.0M | $-36.3M | $-15.8M | $2.1M | $-2.7M |
| EPS | — | — | -0.90 | -0.81 | -0.77 | -0.43 | -0.12 | — |
| Gross Margin | 79.8% | 79.8% | 80.4% | 81.2% | 82.0% | 82.1% | 78.3% | 80.6% |
| Operating Margin | -25.5% | -25.5% | -26.6% | -27.5% | -24.6% | -17.5% | 1.5% | -9.0% |
| Net Margin | -27.7% | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | -6.4% | -10.8% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.82 | 0.82 | 0.62 | 0.51 | 1.13 | 0.32 | 37.61 | — |
| Current Ratio | 3.58 | 3.58 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-29.5M | $-29.5M | $-48.8M | $-46.0M | $-45.5M | $-19.9M | $-5.6M | $-8.9M |
| Returns | ||||||||
| ROE | -67.6% | -67.6% | -49.4% | -35.9% | -70.7% | -22.1% | -472.7% | -134.9% |
| Valuation | ||||||||
| P/B | 2.72 | 2.72 | 4.35 | 5.25 | 21.60 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 1.6% | 1.6% | 11.9% | 31.9% | — | 64.6% | 45.5% | — |
| EPS Growth | — | — | -11.1% | -5.2% | — | -258.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.90 → n/d
Residual
-35.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.